EurekAlert!13d
Fudan team develops a novel CRG-based classification model for IDH1-mutant gliomas, advancing precision therapy optimization
A recent study published in MedComm – Future Medicine by a research team from Fudan University provides an in-depth ...
Medscape2d
Mutant IDH Glioma - Clinical Expert Exchange
The Phase 3 INDIGO Trial was presented in the 2023 ASCO Presidential Plenary session. Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A ...
Hosted on MSN7mon
An 83-year-old Duke professor's breakthrough research leads to new brain cancer drug
What it does: The treatment is taken orally and targets a type of brain cancer referred to as a low grade IDH-mutant glioma. The treatment doesn't cure the cancer but works by halting the activity ...
Hosted on MSN6mon
Breakthrough Hope: A Revolutionary Advance in Treating Brain Cancer Called Glioma– The Drug Vorasidenib Represents The First Progress in 20 Years
A groundbreaking development occurred in August 2024 when the Food and Drug Administration (FDA) approved Vorasidenib for treating both adults and children aged 12 and older with IDH-mutant ...